K
Koji Fujita
Researcher at Wakayama Medical University
Publications - 16
Citations - 356
Koji Fujita is an academic researcher from Wakayama Medical University. The author has contributed to research in topics: Aneurysm & Temozolomide. The author has an hindex of 8, co-authored 16 publications receiving 259 citations.
Papers
More filters
Journal ArticleDOI
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
Hideyuki Arita,Hideyuki Arita,Kai Yamasaki,Yuko Matsushita,Taishi Nakamura,Taishi Nakamura,Asanao Shimokawa,Hirokazu Takami,Hirokazu Takami,Shota Tanaka,Akitake Mukasa,Mitsuaki Shirahata,Saki Shimizu,Kaori Suzuki,Kuniaki Saito,Keiichi Kobayashi,Fumi Higuchi,Takeo Uzuka,Ryohei Otani,Kaoru Tamura,Kazutaka Sumita,Makoto Ohno,Yasuji Miyakita,Naoki Kagawa,Naoya Hashimoto,Ryusuke Hatae,Koji Yoshimoto,Naoki Shinojima,Hideo Nakamura,Yonehiro Kanemura,Yoshiko Okita,Manabu Kinoshita,Kenichi Ishibashi,Tomoko Shofuda,Yoshinori Kodama,Kanji Mori,Yusuke Tomogane,Junya Fukai,Koji Fujita,Yuzo Terakawa,Naohiro Tsuyuguchi,Shusuke Moriuchi,Masahiro Nonaka,Hiroyoshi Suzuki,Makoto Shibuya,Taketoshi Maehara,Nobuhito Saito,Motoo Nagane,Nobutaka Kawahara,Keisuke Ueki,Toshiki Yoshimine,Etsuo Miyaoka,Ryo Nishikawa,Takashi Komori,Yoshitaka Narita,Koichi Ichimura +55 more
TL;DR: The findings suggest that a combination of IDH, TERT, and MGMT refines the classification of grade II-IV diffuse gliomas, and patients with TERT mutant-MGMT unmethylated GBM have the poorest prognosis.
Journal ArticleDOI
Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma.
Takahiro Sasaki,Manabu Kinoshita,Koji Fujita,Junya Fukai,Nobuhide Hayashi,Yuji Uematsu,Yoshiko Okita,Masahiro Nonaka,Shusuke Moriuchi,Takehiro Uda,Naohiro Tsuyuguchi,Naohiro Tsuyuguchi,Hideyuki Arita,Kanji Mori,Kenichi Ishibashi,Koji Takano,Namiko Nishida,Tomoko Shofuda,Ema Yoshioka,Daisuke Kanematsu,Yoshinori Kodama,Masayuki Mano,Naoyuki Nakao,Yonehiro Kanemura +23 more
TL;DR: A magnetic resonance imaging (MRI)-based radiomic model for stratifying prognostic subgroups of newly diagnosed glioblastoma (GBM) patients and predicting O (6)-methylguanine-DNA methyltransferase promotor methylation (pMGMT-met) status of the tumor was established.
Journal ArticleDOI
Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts.
Toru Umehara,Hideyuki Arita,Ema Yoshioka,Tomoko Shofuda,Daisuke Kanematsu,Manabu Kinoshita,Yoshinori Kodama,Masayuki Mano,Naoki Kagawa,Yasunori Fujimoto,Yoshiko Okita,Masahiro Nonaka,Kosuke Nakajo,Takehiro Uda,Naohiro Tsuyuguchi,Naohiro Tsuyuguchi,Junya Fukai,Koji Fujita,Daisuke Sakamoto,Kanji Mori,Haruhiko Kishima,Yonehiro Kanemura +21 more
TL;DR: The diagnosis and prognostication of glioblastoma (GBM) remain to be solely dependent on histopathological findings and few molecular markers, despite the clinical heterogeneity in this entity, and distribution difference in prognostic CNA profiles potentially could cause survival differences across cohorts in clinical studies.
Journal ArticleDOI
Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.
Takahiro Sasaki,Junya Fukai,Yoshinori Kodama,Takanori Hirose,Yoshiko Okita,Shusuke Moriuchi,Masahiro Nonaka,Naohiro Tsuyuguchi,Yuzo Terakawa,Takehiro Uda,Yusuke Tomogane,Manabu Kinoshita,Namiko Nishida,Shuichi Izumoto,Yoshikazu Nakajima,Hideyuki Arita,Kenichi Ishibashi,Tomoko Shofuda,Daisuke Kanematsu,Ema Yoshioka,Masayuki Mano,Koji Fujita,Yuji Uematsu,Naoyuki Nakao,Kanji Mori,Yonehiro Kanemura +25 more
TL;DR: Elderly patients with primary diffuse gliomas have several potential factors for poor prognosis, but resection followed by RT + TMZ could lengthen duration of survival, according to a community-based study reveals characteristics and outcomes of elderly patients in a real-world setting.
Journal ArticleDOI
Reduced Expression of Mismatch Repair Genes MSH6/MSH2 Directly Promotes Pituitary Tumor Growth via the ATR-Chk1 Pathway.
Shinsuke Uraki,Hiroyuki Ariyasu,Asako Doi,Shintaro Kawai,Ken Takeshima,Shuhei Morita,Junya Fukai,Koji Fujita,Hiroto Furuta,Masahiro Nishi,Kokichi Sugano,Naoko Inoshita,Naoyuki Nakao,Shozo Yamada,Takashi Akamizu +14 more
TL;DR: Reduction of MSH6 and MSH2 expression at the messenger RNA and protein levels could be involved in direct PA proliferation by promoting cell-cycle progression or decreasing the rate of apoptosis through interference with the function of the ATR-Chk1 pathway.